Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026)
Alnylam Pharmaceuticals' (ALNY) quarterly Total Liabilities came in at $4.2 billion in Q2 2026, down 2.57% YoY from $4.3 billion in Q2 2025, and up 3.71% on a QoQ basis from $4.1 billion in Q1 2026.
Alnylam Pharmaceuticals (ALNY) Total Liabilities (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals (ALNY) has 18 years of Total Liabilities data on file, last reported at $4.2 billion in Q2 2026.
- Quarterly Total Liabilities fell 2.57% year-over-year to $4.2 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $4.2 billion (down 2.57% YoY) and the FY2025 annual result came in at $4.2 billion, changed 0.1% from the prior year.
- Total Liabilities grew to $4.2 billion in Q2 2026, from $4.1 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $4.6 billion in Q3 2025 to a low of $3.0 billion in Q1 2022.
- A 5-year average of $3.9 billion and a median of $4.0 billion in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2022 — Total Liabilities jumped 32.63% — and 2026, when it decreased 2.57%.
- Tracing ALNY's Total Liabilities over 5 years: stood at $3.7 billion in 2022, then gained by 9.34% to $4.1 billion in 2023, then rose by 3.02% to $4.2 billion in 2024, then rose by 0.1% to $4.2 billion in 2025, then increased by 0.66% to $4.2 billion in 2026.
- The last three Total Liabilities figures came in at $4.2 billion (Q2 2026), $4.1 billion (Q1 2026), and $4.2 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 384.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.20 Bn |
| Mar 31, 2026 | 4.05 Bn |
| Dec 31, 2025 | 4.18 Bn |
| Sep 30, 2025 | 4.62 Bn |
| Jun 30, 2025 | 4.32 Bn |
| Mar 31, 2025 | 4.10 Bn |
| Dec 31, 2024 | 4.17 Bn |
| Sep 30, 2024 | 4.17 Bn |
| Jun 30, 2024 | 4.01 Bn |
| Mar 31, 2024 | 4.04 Bn |
| Dec 31, 2023 | 4.05 Bn |
| Sep 30, 2023 | 4.00 Bn |
| Jun 30, 2023 | 3.81 Bn |
| Mar 31, 2023 | 3.65 Bn |
| Dec 31, 2022 | 3.70 Bn |
| Sep 30, 2022 | 3.60 Bn |
| Jun 30, 2022 | 3.15 Bn |
| Mar 31, 2022 | 3.03 Bn |
| Dec 31, 2021 | 3.06 Bn |
| Sep 30, 2021 | 2.72 Bn |